<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194882</url>
  </required_header>
  <id_info>
    <org_study_id>HUBIN_L_05335</org_study_id>
    <secondary_id>2010-021373-37</secondary_id>
    <secondary_id>U1111-1116-7658</secondary_id>
    <nct_id>NCT01194882</nct_id>
  </id_info>
  <brief_title>Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes</brief_title>
  <official_title>Evaluation of Insuman Implantable 400 IU/ml in Patients With Type 1 Diabetes Treated With the Medtronic MiniMed Implantable Pump System Using Insuplant 400IU/ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump
      refill accuracy during a 4 refill cycle period (i.e. the comparative phase); To assess
      efficacy measured by hemoglobin glycosylated (HBA1c) change in Insuman Implantable 400 IU/ml
      group versus Insuplant 400 IU/ml group after a 4 refill cycle period (i.e. the comparative
      phase).

      Secondary Objective:

      To assess efficacy, safety, refill accuracy evolution and device interventions during the
      open-label treatment period with Insuman To evaluate daily insulin doses To assess
      Anti-Insulin Antibodies (ADAs or AIA) levels during all study phases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration will be displayed in 2 parts as follow:

      Comparative phase (only French patients): 160 +/- 20 days Open label Insuman Implantable
      extension phase (French and European patients): from day 160 up to the grant of Insuman
      implantable marketing authorization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 16, 2010</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refill accuracy between the 2 insulin groups</measure>
    <time_frame>During 4 refill cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Hypoglycaemia (asymptomatic and symptomatic hypoglycaemia, severe and serious symptomatic hypoglycaemia</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hyperglycaemia</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of diabetic ketoacidosis</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody assessments (anti-Insulin antibodies)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">479</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insuman Implantable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insuplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUMAN INSULIN (BIOSYNTHETIC)</intervention_name>
    <description>Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml</description>
    <arm_group_label>Insuman Implantable</arm_group_label>
    <other_name>HR1799</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insuplant</intervention_name>
    <description>Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use
Dose regimen:</description>
    <arm_group_label>Insuplant</arm_group_label>
    <other_name>Human insulin semi synthetic porcine derived</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System
             2007

          2. Glycosylated hemoglobin â‰¤9.0%

          3. Patient showing a percentage of error at refill equal or below 20%

          4. Patient undergoing NaOH rinse procedure of at least 10 minutes period with or without
             flush Or Patient being re-implanted with a new pump (first fill with insulin)

          5. Signed informed consent form prior to enrolment

        Exclusion criteria:

          1. Pump life time &gt; 6 years

          2. Pump battery voltage &lt; 2.6 volts

          3. Pregnancy or childbearing potential without a medically approved form of birth control

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 056-001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-004</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-008</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-003</name>
      <address>
        <city>Dommartin Les Toul</city>
        <zip>54200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-012</name>
      <address>
        <city>Le Mans Cedex 9</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-009</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-007</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-001</name>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-005</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-010</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-011</name>
      <address>
        <city>ST PRIEST EN JAREZ Cedex</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-002</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-006</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528003</name>
      <address>
        <city>Den Haag</city>
        <zip>2512VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Roermond</city>
        <zip>6043CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Zwolle</city>
        <zip>8025AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752-001</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

